Oxford Pharmaceuticals, LLC – FDA 483, Nov 3, 2023
An FDA inspection of Oxford Pharmaceuticals, LLC in Birmingham, AL, revealed significant deficiencies in equipment cleaning and maintenance, quality control investigations, production phase time limits, and laboratory water testing. These issues indicate a lack of adequate controls to prevent contamination, ensure product quality, and properly address product complaints. The findings suggest a need for comprehensive corrective actions to bring the facility into compliance with cGMP regulations.
ID · d7066e3b-80a9-49c8-bb95-75cc0bc54434
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.